within Pharmacolibrary.Drugs.ATC.L;

model L04AB06
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.53,
    Cl             = 0.356 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 50 / 1000000,
    adminCount     = 1,
    Vd             = 0.008,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Golimumab is a fully human monoclonal antibody that targets and neutralizes tumor necrosis factor alpha (TNF-α), a cytokine involved in systemic inflammation. It is approved and used for the treatment of autoimmune conditions such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters derived from healthy and patient populations (including adults with rheumatoid arthritis), both male and female, aged between 18 and 80 years. Parameters are for subcutaneous administration as per typical therapeutic protocols.</p><h4>References</h4><ol><li><p>Sandborn, WJ, et al., &amp; Rutgeerts, P (2014). Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. <i>Gastroenterology</i> 146(1) 85–e15. DOI:<a href=&quot;https://doi.org/10.1053/j.gastro.2013.05.048&quot;>10.1053/j.gastro.2013.05.048</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23735746/&quot;>https://pubmed.ncbi.nlm.nih.gov/23735746</a></p></li><li><p>Hyams, JS, et al., &amp; Strauss, R (2017). Subcutaneous Golimumab in Pediatric Ulcerative Colitis: Pharmacokinetics and Clinical Benefit. <i>Inflammatory bowel diseases</i> 23(12) 2227–2237. DOI:<a href=&quot;https://doi.org/10.1097/MIB.0000000000001262&quot;>10.1097/MIB.0000000000001262</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29140944/&quot;>https://pubmed.ncbi.nlm.nih.gov/29140944</a></p></li><li><p>Zhuang, Y, et al., &amp; Zhou, H (2012). Golimumab pharmacokinetics after repeated subcutaneous and intravenous administrations in patients with rheumatoid arthritis and the effect of concomitant methotrexate: an open-label, randomized study. <i>Clinical therapeutics</i> 34(1) 77–90. DOI:<a href=&quot;https://doi.org/10.1016/j.clinthera.2011.11.015&quot;>10.1016/j.clinthera.2011.11.015</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/22169051/&quot;>https://pubmed.ncbi.nlm.nih.gov/22169051</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L04AB06;
